See the latest news and media coverage for Xaira. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI-driven drug discovery company
xaira.comLast updated
In short: Xaira launched with over $1 billion in capital to revolutionize drug discovery through AI, led by former Stanford President Marc Tessier-Lavigne.
Rachel brings deep biotech and investing experience from Belharra Therapeutics, where she led partnerships with Genentech and Sanofi. She will lead business development and scale AI drug discovery partnerships.
It targets recent MS/PhD graduates for 6-12 month projects advancing models like X-Cell. Applications are now open.
X-Cell is trained on the largest genome-wide perturbation dataset and predicts unseen experiment outcomes. It aims to transform drug discovery.
Bo Wang, SVP & Head of Biomedical AI at Xaira, joins Endpoints News #AIDay2025 to separate hype from reality and highlight future directions for biomedicine.
Xaira Therapeutics today announced the appointment of Dr. Rachel Lane as Senior Vice President, Business Development and Operations, reporting to President and COO Jeff Jonker...
Funders committed nearly $1 billion toward this AI company. Here's its next act.
Since Xaira's eye-popping $1 billion fundraise in 2024, the company has said relatively little in public. | What has Xaira been doing since its $1...
State-of-the-art AI model accurately predicting unseen biological experiments X-Cell is trained on X-Atlas/Pisces, the largest and most context-diverse genome-wide perturbation dataset ever reported Powered by...
Track Xaira and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Xaira and other trending companies.